Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors

Journal of Clinical Oncology

Volumn 24, Issue 10, 2006, Pages 1491-1498

  Beerepoot, Laurens V ^a   Radema, Sandra A ^a   Witteveen, Els O ^a   Thomas, Tawnie ^a   Wheeler, Catherine ^a   Kempin, Sanford ^a   Voest, Emile E ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; N ACETYLCOLCHINOL PHOSPHATE; ANTINEOPLASTIC AGENT; N ACETYLCOCHINOL O PHOSPHATE; N-ACETYLCOCHINOL-O-PHOSPHATE; ORGANOPHOSPHORUS COMPOUND;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BLOOD VESSEL INJURY; BREAST CARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BRAIN LEVEL; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG MUSCLE LEVEL; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; ENDOTHELIUM CELL; ESOPHAGEAL ADENOCARCINOMA; FATIGUE; FEMALE; FEVER; HEAD AND NECK CARCINOMA; HEADACHE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERGLYCEMIA; HYPERHIDROSIS; HYPERKALEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; HYPOXIA; KIDNEY CARCINOMA; LIMB PAIN; LUNG CARCINOMA; LUNG CREPITATION; LUNG DISEASE; LUNG EMBOLISM; MALAISE; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NAUSEA AND VOMITING; NIGHT SWEAT; NONHUMAN; PARALYTIC ILEUS; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RETCHING; RIGOR; SIDE EFFECT; SOMNOLENCE; THORAX PAIN; THROMBOEMBOLISM; VERTIGO; VOMITING; BLOOD; CELL COUNT; DRUG EFFECT; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; MIDDLE AGED; NEOPLASM;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CELL COUNT; CREATINE KINASE; ENDOTHELIAL CELLS; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; ORGANOPHOSPHORUS COMPOUNDS; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 33645732100     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.7458     Document Type: Article

References (33)

1. Denekamp J: Endothelial cell proliferation as a novel approach to targeting tumour therapy. Br J Cancer 45:136-139, 1982
2. Gotlieb AI: The endothelial cytoskeleton: Organization in normal and regenerating endothelium. Toxicol Pathol 18:603-617, 1990
3. Chaplin DJ, Pettit GR, Parkins CS, et al: Anti-vascular approaches to solid tumour therapy: Evaluation of tubulin binding agents. Br J Cancer 27:S86-S88, 1996
4. Hill SA, Lonergan SJ, Denekamp J, et al: Vinca alkaloids: Anti-vascular effects in a murine tumour. Eur J Cancer 29A:1320-1324, 1993
5. Watts ME, Woodcock M, Arnold S, et al: Effects of novel and conventional anti-cancer agents on human endothelial permeability: Influence of tumour secreted factors. Anticancer Res 17:71-75, 1997
6. Chaplin DJ, Hill SA: The development of combretastatin A4 phosphate as a vascular targeting agent. Int J Radiat Oncol Biol Phys 54:1491-1496, 2002
7. Davis PD, Dougherty GJ, Blakey DC, et al: ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 62:7247-7253, 2002
8. Blakey DC, Westwood FR, Walker M, et al: Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 8:1974-1983, 2002
9. Micheletti G, Poli M, Borsoni P, et al: Vascular-targeting activity of ZD6126, a novel tubulin-binding agent. Cancer Res 63:1534-1537, 2003
10. Dowlati A, Robertson K, Cooney M, et al: A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 62:3408-3416, 2002
11. Rustin GJ, Galbraith SM, Anderson H, et al: Phase I clinical trial of weekly combretastatin A4 phosphate: Clinical and pharmacokinetic results. J Clin Oncol 21:2815-2822, 2003
12. Stevenson JP, Rosen M, Sun W, et al: Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: Magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 21:4428-4438, 2003
13. Cooney MM, Radivoyevitch T, Dowlati A, et al: Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res 10:96-100, 2004
14. Phillips RW. Phase I study of N-acetylcolchinol (NSC-51045). Cancer Chemother Rep 42:29-34, 1964
15. Robinson SP, McIntyre DJ, Checkley D, et al: Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging. Br J Cancer 88:1592-1597, 2003
16. Davis PD, Dougherty GJ, Blakey DC, et al: ZD6126: A novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 62:7247-7253, 2002
17. Siemann DW, Rojiani AM: Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 54:1512-1517, 2002
18. Siemann DW, Rojiani AM: Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 53:164-171, 2002
19. O'Quigley J, Pepe M, Fisher L: Continual reassessment method: A practical design for phase 1 clinical trials in cancer. Biometrics 46:33-418, 1990
20. Goodman SN, Zahurak ML, Piantadosi S: Some practical improvements in the continual reassessment method for phase I studies. Stat Med 14:1149-1161, 1995
21. Faries D: Practical modifications of the continual reassessment method for phase I cancer clinical trials. J Biopharm Stat 4:147-164, 1994
22. Division of Cancer Treatment: Guidelines for Reporting of Adverse Drug Reactions. Bethesda, MD, National Cancer Institute, 1988
23. Green S, Weiss GR: Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 10:239-253, 1992
24. Beerepoot LV, Mehra N, Vermaat JS, et al: Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann Oncol 15:139-145, 2004
25. Mutin M, Canavy I, Blann A, et al: Direct evidence of endothelial injury in acute myocardial infarction and unstable angina by demonstration of circulating endothelial cells. Blood 93:2951-2958, 1999
26. Solovey A, Lin Y, Browne P, et al: Circulating activated endothelial cells in sickle cell anemia. N Engl J Med 337:1584-1590, 1997
27. Woywodt A, Streiber F, De Groot K, et al: Circulating endothelial cells as markers for ANCA-associated small-vessel vasculitis. Lancet 361:206-210, 2003
28. Lee AY, Levine MN: Venous thromboembolism and cancer: Risks and outcomes. Circulation 107:117-121, 2003
29. Rafii S, Lyden D, Benezra R, et al: Vascular and haematopoietic stem cells: Novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2:826-835, 2002
30. Bertolini F, Mingrone W, Alietti A, et al: Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis: Analysis of clinical results and of surrogate angiogenesis markers. Ann Oncol 12:987-990, 2001
31. Schuch G, Heymach JV, Nomi M, et al: Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells. Cancer Res 63:8345-8350, 2003
32. Goertz DE, Yu JL, Kerbel RS, et al: High-frequency Doppler ultrasound monitors the effects of antivascular therapy on tumor blood flow. Cancer Res 62:6371-6375, 2002
33. Evelhoch JL, LoRusso PM, He Z, et al: Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin Cancer Res 10:3650-3657, 2004